Lowers the risk of stroke and systemic embolism. ANDA 208039, held by Aurobindo Pharma. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 208039 (Dabigatran Etexilate Mesylate), held by Aurobindo Pharma, was first approved by FDA on May 14, 2025, with 0 approved supplements and 0 published complete response letters.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagula…
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 14, 2025 | Original application | Approved | None posted |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters